Logo image of ABVC

ABVC BIOPHARMA INC (ABVC) Stock Fundamental Analysis

NASDAQ:ABVC - Nasdaq - US00091F3047 - Common Stock - Currency: USD

0.6996  +0.11 (+19.59%)

After market: 0.69 -0.01 (-1.37%)

Fundamental Rating

2

Overall ABVC gets a fundamental rating of 2 out of 10. We evaluated ABVC against 571 industry peers in the Biotechnology industry. ABVC may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ABVC is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ABVC had negative earnings in the past year.
In the past year ABVC has reported a negative cash flow from operations.
In the past 5 years ABVC always reported negative net income.
ABVC had a negative operating cash flow in each of the past 5 years.
ABVC Yearly Net Income VS EBIT VS OCF VS FCFABVC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

The Return On Assets of ABVC (-57.00%) is comparable to the rest of the industry.
ABVC's Return On Equity of -98.62% is in line compared to the rest of the industry. ABVC outperforms 46.18% of its industry peers.
Industry RankSector Rank
ROA -57%
ROE -98.62%
ROIC N/A
ROA(3y)-110.94%
ROA(5y)-93.93%
ROE(3y)-266.76%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ABVC Yearly ROA, ROE, ROICABVC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2K -2K -4K -6K

1.3 Margins

ABVC has a Gross Margin of 72.54%. This is amongst the best in the industry. ABVC outperforms 84.01% of its industry peers.
ABVC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 72.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABVC Yearly Profit, Operating, Gross MarginsABVC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K -40K -50K

More info and screens

1

2. Health

2.1 Basic Checks

ABVC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ABVC has more shares outstanding
ABVC has more shares outstanding than it did 5 years ago.
ABVC has a better debt/assets ratio than last year.
ABVC Yearly Shares OutstandingABVC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M
ABVC Yearly Total Debt VS Total AssetsABVC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M

2.2 Solvency

Based on the Altman-Z score of -7.84, we must say that ABVC is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -7.84, ABVC is doing worse than 69.80% of the companies in the same industry.
ABVC has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
ABVC's Debt to Equity ratio of 0.10 is on the low side compared to the rest of the industry. ABVC is outperformed by 66.96% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -7.84
ROIC/WACCN/A
WACC8.83%
ABVC Yearly LT Debt VS Equity VS FCFABVC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M

2.3 Liquidity

ABVC has a Current Ratio of 0.34. This is a bad value and indicates that ABVC is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.34, ABVC is doing worse than 95.03% of the companies in the same industry.
ABVC has a Quick Ratio of 0.34. This is a bad value and indicates that ABVC is not financially healthy enough and could expect problems in meeting its short term obligations.
ABVC's Quick ratio of 0.34 is on the low side compared to the rest of the industry. ABVC is outperformed by 94.49% of its industry peers.
Industry RankSector Rank
Current Ratio 0.34
Quick Ratio 0.34
ABVC Yearly Current Assets VS Current LiabilitesABVC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 72.30% over the past year.
Looking at the last year, ABVC shows a very negative growth in Revenue. The Revenue has decreased by -31.65% in the last year.
Measured over the past years, ABVC shows a very strong growth in Revenue. The Revenue has been growing by 72.43% on average per year.
EPS 1Y (TTM)72.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.16%
Revenue 1Y (TTM)-31.65%
Revenue growth 3Y-31.78%
Revenue growth 5Y72.43%
Sales Q2Q%2351.39%

3.2 Future

The Earnings Per Share is expected to decrease by -28.17% on average over the next years. This is quite bad
ABVC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 245.77% yearly.
EPS Next Y-57.14%
EPS Next 2Y-28.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y245.77%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ABVC Yearly Revenue VS EstimatesABVC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M
ABVC Yearly EPS VS EstimatesABVC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ABVC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABVC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABVC Price Earnings VS Forward Price EarningsABVC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABVC Per share dataABVC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A cheap valuation may be justified as ABVC's earnings are expected to decrease with -28.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.17%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ABVC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABVC BIOPHARMA INC

NASDAQ:ABVC (2/21/2025, 8:00:00 PM)

After market: 0.69 -0.01 (-1.37%)

0.6996

+0.11 (+19.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)03-11 2025-03-11/amc
Inst Owners2.95%
Inst Owner Change79.38%
Ins Owners15.83%
Ins Owner Change0%
Market Cap9.08M
Analysts43.33
Price TargetN/A
Short Float %2.17%
Short Ratio0.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.81
P/FCF N/A
P/OCF N/A
P/B 1.09
P/tB 1.09
EV/EBITDA N/A
EPS(TTM)-0.97
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-0.14
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS0.04
BVpS0.64
TBVpS0.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -57%
ROE -98.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 72.54%
FCFM N/A
ROA(3y)-110.94%
ROA(5y)-93.93%
ROE(3y)-266.76%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.34
Quick Ratio 0.34
Altman-Z -7.84
F-Score4
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)291.44%
Cap/Depr(5y)N/A
Cap/Sales(3y)10.61%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.16%
EPS Next Y-57.14%
EPS Next 2Y-28.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-31.65%
Revenue growth 3Y-31.78%
Revenue growth 5Y72.43%
Sales Q2Q%2351.39%
Revenue Next Year-100%
Revenue Next 2Y245.77%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y80.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80.06%
OCF growth 3YN/A
OCF growth 5YN/A